These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1471 related articles for article (PubMed ID: 28940194)

  • 61. Pertuzumab, a novel HER dimerization inhibitor, inhibits the growth of human lung cancer cells mediated by the HER3 signaling pathway.
    Sakai K; Yokote H; Murakami-Murofushi K; Tamura T; Saijo N; Nishio K
    Cancer Sci; 2007 Sep; 98(9):1498-503. PubMed ID: 17627612
    [TBL] [Abstract][Full Text] [Related]  

  • 62. HER3 intracellular domains play a crucial role in HER3/HER2 dimerization and activation of downstream signaling pathways.
    Choi BK; Cai X; Yuan B; Huang Z; Fan X; Deng H; Zhang N; An Z
    Protein Cell; 2012 Oct; 3(10):781-9. PubMed ID: 22983903
    [TBL] [Abstract][Full Text] [Related]  

  • 63. AZD8931, an equipotent, reversible inhibitor of signaling by epidermal growth factor receptor, ERBB2 (HER2), and ERBB3: a unique agent for simultaneous ERBB receptor blockade in cancer.
    Hickinson DM; Klinowska T; Speake G; Vincent J; Trigwell C; Anderton J; Beck S; Marshall G; Davenport S; Callis R; Mills E; Grosios K; Smith P; Barlaam B; Wilkinson RW; Ogilvie D
    Clin Cancer Res; 2010 Feb; 16(4):1159-69. PubMed ID: 20145185
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Prognosis of esophageal squamous cell carcinoma in patients positive for human epidermal growth factor receptor family can be improved by initial chemotherapy with docetaxel, fluorouracil, and cisplatin.
    Yamamoto Y; Yamai H; Seike J; Yoshida T; Takechi H; Furukita Y; Kajiura K; Minato T; Bando Y; Tangoku A
    Ann Surg Oncol; 2012 Mar; 19(3):757-65. PubMed ID: 21947696
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Selective formation of ErbB-2/ErbB-3 heterodimers depends on the ErbB-3 affinity of epidermal growth factor-like ligands.
    Stortelers C; van der Woning SP; Jacobs-Oomen S; Wingens M; van Zoelen EJ
    J Biol Chem; 2003 Apr; 278(14):12055-63. PubMed ID: 12556529
    [TBL] [Abstract][Full Text] [Related]  

  • 66. AZD8931, an equipotent, reversible inhibitor of signaling by epidermal growth factor receptor (EGFR), HER2, and HER3: preclinical activity in HER2 non-amplified inflammatory breast cancer models.
    Mu Z; Klinowska T; Dong X; Foster E; Womack C; Fernandez SV; Cristofanilli M
    J Exp Clin Cancer Res; 2014 May; 33(1):47. PubMed ID: 24886365
    [TBL] [Abstract][Full Text] [Related]  

  • 67. ErbB activation signatures as potential biomarkers for anti-ErbB3 treatment in HNSCC.
    Alvarado D; Ligon GF; Lillquist JS; Seibel SB; Wallweber G; Neumeister VM; Rimm DL; McMahon G; LaVallee TM
    PLoS One; 2017; 12(7):e0181356. PubMed ID: 28723928
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Differential modulation of proliferation, matrix metalloproteinase expression and invasion of human head and neck squamous carcinoma cells by c-erbB ligands.
    O-charoenrat P; Rhys-Evans P; Court WJ; Box GM; Eccles SA
    Clin Exp Metastasis; 1999; 17(7):631-9. PubMed ID: 10845563
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Epidermal Growth Factor (EGF) Autocrine Activation of Human Platelets Promotes EGF Receptor-Dependent Oral Squamous Cell Carcinoma Invasion, Migration, and Epithelial Mesenchymal Transition.
    Chen R; Jin G; Li W; McIntyre TM
    J Immunol; 2018 Oct; 201(7):2154-2164. PubMed ID: 30150285
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Roles of human epidermal growth factor receptor family in pulmonary lymphangioleiomyomatosis.
    Kobayashi K; Miki Y; Saito R; Adachi K; Seyama K; Okada Y; Sasano H
    Hum Pathol; 2018 Nov; 81():121-130. PubMed ID: 30030119
    [TBL] [Abstract][Full Text] [Related]  

  • 71. HDAC inhibitor vorinostat enhances the antitumor effect of gefitinib in squamous cell carcinoma of head and neck by modulating ErbB receptor expression and reverting EMT.
    Bruzzese F; Leone A; Rocco M; Carbone C; Piro G; Caraglia M; Di Gennaro E; Budillon A
    J Cell Physiol; 2011 Sep; 226(9):2378-90. PubMed ID: 21660961
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Study of inhibition effect of herceptin on interaction between heregulin and erbB receptors HER3/HER2 by single-molecule force spectroscopy.
    Shi X; Xu L; Yu J; Fang X
    Exp Cell Res; 2009 Oct; 315(16):2847-55. PubMed ID: 19497323
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Epidermal growth factor receptor and mutant p53 expand an esophageal cellular subpopulation capable of epithelial-to-mesenchymal transition through ZEB transcription factors.
    Ohashi S; Natsuizaka M; Wong GS; Michaylira CZ; Grugan KD; Stairs DB; Kalabis J; Vega ME; Kalman RA; Nakagawa M; Klein-Szanto AJ; Herlyn M; Diehl JA; Rustgi AK; Nakagawa H
    Cancer Res; 2010 May; 70(10):4174-84. PubMed ID: 20424117
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Pathogenic HER3 dimerization domain mutations create a structural bias towards un-conventional EGFR-HER3 signalling axis in breast cancer.
    Dey P; Gadewal N; De A
    Int J Biol Macromol; 2023 Jul; 242(Pt 2):124765. PubMed ID: 37156315
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Epidermal growth factor contains both positive and negative determinants for interaction with ErbB-2/ErbB-3 heterodimers.
    Stortelers C; van De Poll ML; Lenferink AE; Gadellaa MM; van Zoelen C; van Zoelen EJ
    Biochemistry; 2002 Apr; 41(13):4292-301. PubMed ID: 11914075
    [TBL] [Abstract][Full Text] [Related]  

  • 76. ErbB3 expression and dimerization with EGFR influence pancreatic cancer cell sensitivity to erlotinib.
    Frolov A; Schuller K; Tzeng CW; Cannon EE; Ku BC; Howard JH; Vickers SM; Heslin MJ; Buchsbaum DJ; Arnoletti JP
    Cancer Biol Ther; 2007 Apr; 6(4):548-54. PubMed ID: 17457047
    [TBL] [Abstract][Full Text] [Related]  

  • 77. The pan-erbB tyrosine kinase inhibitor CI-1033 inhibits human esophageal cancer cells in vitro and in vivo.
    Ako E; Yamashita Y; Ohira M; Yamazaki M; Hori T; Kubo N; Sawada T; Hirakawa K
    Oncol Rep; 2007 Apr; 17(4):887-93. PubMed ID: 17342332
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Mig6 not only inhibits EGFR and HER2 but also targets HER3 and HER4 in a differential specificity: Implications for targeted esophageal cancer therapy.
    Zhong H; He J; Yu J; Li X; Mei Y; Hao L; Wu X
    Biochimie; 2021 Nov; 190():132-142. PubMed ID: 34293452
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Heregulin activation of extracellular acidification in mammary carcinoma cells is associated with expression of HER2 and HER3.
    Chan SD; Antoniucci DM; Fok KS; Alajoki ML; Harkins RN; Thompson SA; Wada HG
    J Biol Chem; 1995 Sep; 270(38):22608-13. PubMed ID: 7673253
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Androgen-independent prostate cancer cells circumvent EGFR inhibition by overexpression of alternative HER receptors and ligands.
    Carrión-Salip D; Panosa C; Menendez JA; Puig T; Oliveras G; Pandiella A; De Llorens R; Massaguer A
    Int J Oncol; 2012 Sep; 41(3):1128-38. PubMed ID: 22684500
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 74.